SCHEMBL15112848

SCHEMBL15112848

COc1ccc(CC(=O)Nc2nc3cc(C)c(C)cc3s2)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.62
MAPK1 P28482 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
KDM4E B2RXH2 1/20 0.62
TSHR P16473 1/20 0.62
MAPK10 P53779 1/20 0.62
GAA P10253 1/20 0.60
MAPT P10636 1/20 0.60
CSNK1D P48730 7/20 0.60
ROCK2 O75116 1/20 0.57
GLS O94925 1/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
POLB P06746 1/20 0.57
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15489038 0.93 CSNK1D (0.60) LMNAMAPK1SMN1; SMN2KDM4ETSHR
SCHEMBL15113374 0.92 GAA (0.64) LMNAMAPK1SMN1; SMN2KDM4ETSHR
SCHEMBL25840648 0.88 ROCK2 (0.61) LMNAMAPK1SMN1; SMN2KDM4ETSHR
SCHEMBL15112849 0.88 CSNK1D (0.70) LMNAMAPK1SMN1; SMN2KDM4ETSHR
SCHEMBL15113372 0.86 CSNK1D (0.81) SMN1; SMN2TSHRMAPK10GAAMAPT
SCHEMBL15112843 0.85 CSNK1D (0.71) LMNAGAAMAPTCSNK1DPOLB
SCHEMBL15112847 0.85 CSNK1D (0.72) LMNASMN1; SMN2GAAMAPTCSNK1D
SCHEMBL17410545 0.85 GAA (0.64) LMNAMAPK1SMN1; SMN2KDM4ETSHR
SCHEMBL15112850 0.84 L3MBTL1 (0.63) LMNAMAPK1SMN1; SMN2KDM4ETSHR
SCHEMBL20013893 0.84 ROCK2 (0.60) LMNAMAPK1SMN1; SMN2KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170152485-A1 Method for Inducing Cardiac Differentiation of Pluripotent Stem Cell with Low-Molecular Compounds KYOTO UNIVERSITY (JP) 2017-06-01 US disclosed
US-9587220-B2 Method for inducing cardiac differentiation of pluripotent stem cell KYOTO UNIVERSITY (JP) 2017-03-07 US disclosed
US-20160002600-A1 COMPOSITION FOR PROMOTING CARDIAC DIFFERENTIATION OF PLURIPOTENT STEM CELL COMPRISING EGFR INHIBITOR KYOTO UNIVERSITY (JP) 2016-01-07 US disclosed
US-8658425-B2 Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells KYOTO UNIVERSITY (JP) 2014-02-25 US disclosed
US-20130183753-A1 METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS KYOTO UNIVERSITY (JP) 2013-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130183753-A1 METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS TNNI3, MYLK2, TNNT2 LMNA 340/4885MAPK1 3064/4885SMN1; SMN2 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.